10-K: Bioethics Ltd. Reports Widening Losses, Failed Merger

Bioethics, Ltd., a long-standing shell company, reported a significant increase in net losses and a worsening working capital deficit for fiscal year 2024, compounded by the expiration of a key merger agreement.

Summary

• Bioethics, Ltd. remains a shell company, incorporated in 1990, with no active business operations and no significant revenues generated to date.
• The company is actively seeking business opportunities for acquisition or participation.
• For the fiscal year ended December 31, 2024, the company reported a net loss of $176,955, a substantial increase from the $97,149 net loss in 2023.
• The working capital deficit widened to $931,220 at December 31, 2024, up from $776,265 at December 31, 2023.
• Current liabilities increased to $945,884 in 2024 from $776,403 in 2023.
• An agreement and plan of merger with SILQ Technologies Corporation, entered into on September 20, 2024, has since expired and was not extended.
• The company's accumulated deficit reached $1,454,834 as of December 31, 2024.

Sentiment

Score: 2

Explanation: The company exhibits severe financial distress with increasing losses, a widening deficit, and no operational revenue. The failure of a key merger agreement further compounds the negative outlook, indicating a lack of progress in its core strategy as a shell company. While some cash was raised, it primarily offsets operational burn and does not signal a path to profitability.

Positives

• Cash and cash equivalents increased to $14,664 at December 31, 2024, from $138 at December 31, 2023, primarily due to financing activities.
• The company continues to actively seek and evaluate potential business opportunities for acquisition or participation.
• Management believes the weakness in internal control due to lack of segregation of duties is mitigated by the company's shell status, limited transactions, and use of an independent accounting firm.

Negatives

• Net loss significantly increased to $176,955 in 2024 from $97,149 in 2023.
• Working capital deficit worsened to $931,220 in 2024 from $776,265 in 2023.
• Current liabilities increased to $945,884 in 2024 from $776,403 in 2023.
• Accumulated deficit grew to $1,454,834 in 2024 from $1,277,879 in 2023.
• The merger agreement with SILQ Technologies Corporation expired and was not extended, indicating a failure to secure a key strategic opportunity.
• General and administrative expenses more than doubled to $122,817 in 2024 from $50,442 in 2023.
• Interest expense increased to $54,138 in 2024 from $46,707 in 2023.
• Net cash used by operating activities increased substantially to $150,429 in 2024 from $22,307 in 2023.
• The company has incurred losses since inception and has no ongoing operations, raising substantial doubt about its ability to continue as a going concern.

Risks

• The company is a shell company with no active business operations, facing substantial risks associated with the search for and acquisition of business opportunities.
• There is no assurance that the company will be able to locate a suitable business enterprise or acquire it on acceptable terms.
• If a business opportunity is acquired, there is no assurance it will perform in accordance with management's expectations or result in profit or share price appreciation.
• Any acquisition may involve the issuance of a controlling interest, diluting existing stockholders' equity interests and potentially reducing net tangible asset value per share.
• Management has broad discretion in selecting a business opportunity, which may have an adverse impact on current stockholders.
• The company has limited resources and an inability to provide prospective business opportunities with additional capital.
• Costs incurred in investigating business opportunities may not be recoverable if a decision is made not to participate or if a transaction fails to consummate.
• The company faces substantial competition in locating business opportunities from entities with significantly greater experience, resources, and managerial capabilities.
• The company's common stock trades sporadically on the OTC Pink Marketplace and is subject to 'penny stock' regulations, which may restrict trading and deter broker-dealers.
• The company's financial statements have been prepared assuming it will continue as a going concern, but incurred losses since inception and no ongoing operations raise substantial doubt about this ability.
• The company's internal control over financial reporting is not effective due to the principal executive and financial officers being the same person, which does not allow for segregation of duties or board oversight.

Future Outlook

Management intends to continue seeking, investigating, and acquiring interests in business opportunities across various industries and geographical locations. Future operations are anticipated to result in increased cash requirements and potentially more employees once an acquisition is made. The company plans to raise necessary additional funds through loans, stock sales, or business combinations.

Management Comments

• Management has not established any firm criteria with respect to the type of business with which the Company desires to become involved and will consider participating in a business enterprise in a variety of different industries or areas with no limitation as to the geographical location of the enterprise.
• Management believes that it is in the best interest of the Company to acquire or participate in a business enterprise, though there is no assurance of success.
• The Chief Executive Officer/Chief Financial Officer believes the weakness [in internal control due to lack of segregation of duties] is mitigated by the Company's status as a shell company with no significant assets or liabilities, no business operations, a limited number of transactions each year, and the preparation of quarterly financial statements by an independent accounting firm.

Industry Context

Bioethics, Ltd. operates as a long-standing shell company, a common structure for entities seeking to acquire an operating business to become publicly traded. However, its prolonged period without active operations since 1990 and consistent losses highlight the significant challenges and competitive pressures in identifying and successfully integrating suitable business opportunities. The failure of the SILQ Technologies merger underscores the high risk and difficulty in executing such transactions, especially for companies with limited internal resources and a history of financial deficits. The company's reliance on financing activities to sustain its minimal operations is typical for shell companies but also indicates a lack of self-sufficiency.

Comparison to Industry Standards

• Unlike many shell companies that are formed with a specific industry focus or a limited timeframe for acquisition, Bioethics, Ltd. has been a shell since 1990 with no defined criteria for its target business, which is an unusually broad and potentially inefficient approach compared to more focused Special Purpose Acquisition Companies (SPACs) or private equity funds.
• The company's consistent net losses and increasing working capital deficit are indicative of a shell company that has failed to execute its primary objective of acquiring a profitable business, contrasting sharply with successful shell companies or SPACs that either complete an acquisition or liquidate within a defined period.
• The reliance on related-party loans and the issuance of convertible notes at low conversion prices (e.g., $0.25-$0.50 per share in recent issuances) suggests a challenging fundraising environment and potentially high dilution for existing shareholders, which is a common but often detrimental characteristic of distressed or long-term shell entities.
• The lack of formal corporate governance committees (audit, compensation, nominating) and the concentration of executive roles in one individual (Mark Scharmann) fall below best practices for public companies, even smaller reporting companies, and could raise concerns for institutional investors seeking robust oversight.

Corporate Governance

Related Party Transactions

• The company pays its President $500 per month for the use of his personal residence as the company's office and mailing address, totaling $6,000 annually. An amount of $1,500 remained payable at December 31, 2024.
• The company has an unsecured promissory note with its President, with a balance of $242,439 at December 31, 2024 (up from $204,484 in 2023), accruing interest at 12% per annum and due on demand. The company paid $85,000 of accrued interest during 2024.
• The company has a promissory note with a newly affiliated party for $43,250, accruing interest at 10% per annum and due on demand.

Stakeholder Impact

• Shareholders face significant dilution risk from future stock issuances for acquisitions or capital raises, as well as potential reduction in net tangible asset value per share. The penny stock designation and sporadic trading limit liquidity and market value. The company's going concern risk poses a threat to the entire investment.
• Creditors, including related parties, face repayment uncertainty given the company's ongoing losses and reliance on future capital raises.
• Employees (currently none) of any future acquired business would face integration risks and uncertainty given the acquiring entity's financial instability and history as a shell company.

Next Steps

• Continue to seek, investigate, and acquire an interest in a suitable business opportunity.
• Management proposes to raise additional funds through loans, additional sales of common stock, or a possible business combination.

Key Dates

Recommendation

Bioethics, Ltd. presents a highly speculative and distressed investment profile. The company has been a shell for over three decades with no active operations or revenue, consistently incurring significant losses and accumulating a substantial deficit. The widening working capital deficit and increased cash burn indicate a deteriorating financial position. The failure of the merger agreement with SILQ Technologies Corporation, a critical strategic initiative, highlights the company's inability to execute its core business plan. Furthermore, the 'going concern' uncertainty, penny stock designation, and weak corporate governance (lack of independent oversight, single officer for multiple key roles) collectively point to severe fundamental weaknesses and high investment risk. Future capital raises are likely to be highly dilutive, and there is no clear path to profitability or value creation for shareholders.

Keywords

shell company, Bioethics, 10-K, financial report, corporate acquisition, OTC Pink, penny stock, financial deficit, going concern, merger failure, capital raise, corporate governance